EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial

Yang Qu, Zhen-Ni Guo, Shuang Qi, Reziya Abuduxukuer, Peng Zhang, Huimin Li, Xin-Ni Lv, Zeng-Xin Xu, Yi Yang iD, ENHANCE Protocol Steering Group

European Stroke Journal · 2026

DOI: 10.1093/esj/aakag084 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift European Stroke Journal, 2026. Verfasst von Yang Qu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Stroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Minocycline, Cerebral Hemorrhage, Anti-Bacterial Agents, Neuroprotective Agents. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Department of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although minocycline is a multi-target neuroprotective drug, its potential benefit in patients with ICH remains unclear. This study primarily aims to assess the efficacy and safety of minocycline for the treatment of ICH. Study design Efficacy and Safety of Minocycline in the Treatment of ICH (ENHANCE) is an ongoing prospective, multicentre, randomised, open-label, blinded-endpoint clinical trial. A total of 1248 patients with ICH within 24 h of onset will be randomly assigned to the minocycline or control group at a ratio of 1:1. The minocycline group will receive an initial dose of 200 mg minocycline hydrochloride capsules in addition to the guideline-based treatment, followed by 100 mg orally every 12 h for 7 days, resulting in a total of 14 administrations. The control group will receive only the guideline-based treatment. Study endpoints The primary efficacy outcome measure will be the proportion of patients with good functional outcomes (mRS score, 0–2) at 180 days. Safety outcome measures will include all adverse events and severe adverse events occurring during the study period. Summary The ENHANCE trial is designed to evaluate the effectiveness and safety of minocycline in the treatment of ICH.

Trial registration

Chinese Clinical Trials Registry identifier: ChiCTR2500114607.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MinocyclineCerebral HemorrhageAnti-Bacterial AgentsNeuroprotective AgentsHumansTreatment OutcomeFemaleMaleRandomized Controlled Trials as TopicMiddle AgedProspective StudiesMulticenter Studies as TopicResearch DesignAdultAged

Stichwörter der Autor:innen

clinical trialintracerebral haemorrhageminocyclineprotocol

Substanzen

MinocyclineAnti-Bacterial AgentsNeuroprotective Agents

Autor:innen und Institutionen

  • Stroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
  • Neuroscience Research Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China.

ORCID-Profile: Yi Yang

Förderung

  • Science and Technology Department of Jilin Province

Zitieren

APA

Qu, Y., Guo, Z. N., Qi, S., Abuduxukuer, R., Zhang, P., Li, H., Lv, X. N., Xu, Z. X., Yang, Y., & ENHANCE Protocol Steering Group (2026). Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial. European Stroke Journal. https://doi.org/10.1093/esj/aakag084

Vancouver

Qu Y, Guo ZN, Qi S, Abuduxukuer R, Zhang P, Li H, et al. Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial. European Stroke Journal. 2026. doi:10.1093/esj/aakag084

BibTeX
@article{Qu2026,
  author = {Qu, Yang and Guo, Zhen-Ni and Qi, Shuang and Abuduxukuer, Reziya and Zhang, Peng and Li, Huimin and Lv, Xin-Ni and Xu, Zeng-Xin and Yang, Yi and ENHANCE Protocol Steering Group, ENHANCE Protocol Steering Group},
  title = {Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial},
  journal = {European Stroke Journal},
  year = {2026},
  doi = {10.1093/esj/aakag084}
}
Kostenlos starten →